The OncoAlert Network 🚨
@oncoalert.bsky.social
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨
www.OncoAlert360.com
www.OncoAlert360.com
Straight from #UromigosLive 2025
A GREAT discussion on ADC use in #BladderCancer
The possibility of Combination Trials, seeing the trade off between Toxicity and the Long Term Benefit
Complete Video Here x.com/Uromigos/sta...
A GREAT discussion on ADC use in #BladderCancer
The possibility of Combination Trials, seeing the trade off between Toxicity and the Long Term Benefit
Complete Video Here x.com/Uromigos/sta...
November 8, 2025 at 8:09 PM
Straight from #UromigosLive 2025
A GREAT discussion on ADC use in #BladderCancer
The possibility of Combination Trials, seeing the trade off between Toxicity and the Long Term Benefit
Complete Video Here x.com/Uromigos/sta...
A GREAT discussion on ADC use in #BladderCancer
The possibility of Combination Trials, seeing the trade off between Toxicity and the Long Term Benefit
Complete Video Here x.com/Uromigos/sta...
Dear Colleagues in #ESMO25
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨will be Live from Lisbon covering this Great meeting
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨will be Live from Lisbon covering this Great meeting
November 7, 2025 at 1:47 PM
Dear Colleagues in #ESMO25
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨will be Live from Lisbon covering this Great meeting
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨will be Live from Lisbon covering this Great meeting
Join us for a discussion on rPFS as a surrogate for OS in mHSPC #ProstateCancer
Available now 👉 mirrorsmed.org/m2p-rpfs-sur...
What does it mean for clinical practice? How should it guide treatment decisions?
📺 Join Neal Shore, MD & Alicia Morgans, MD
Available now 👉 mirrorsmed.org/m2p-rpfs-sur...
What does it mean for clinical practice? How should it guide treatment decisions?
📺 Join Neal Shore, MD & Alicia Morgans, MD
November 7, 2025 at 1:41 PM
Join us for a discussion on rPFS as a surrogate for OS in mHSPC #ProstateCancer
Available now 👉 mirrorsmed.org/m2p-rpfs-sur...
What does it mean for clinical practice? How should it guide treatment decisions?
📺 Join Neal Shore, MD & Alicia Morgans, MD
Available now 👉 mirrorsmed.org/m2p-rpfs-sur...
What does it mean for clinical practice? How should it guide treatment decisions?
📺 Join Neal Shore, MD & Alicia Morgans, MD
A warm invite to join a live, free interactive webinar on November 4, 2025, at CET REGISTER👉
us02web.zoom.us/webinar/regi...
Fred Saad and Marc-Oliver Grimm @grimm_mo will lead an engaging case-based discussion on triplet therapy in metastatic hormone-sensitive #ProstateCancer (mHSPC).
us02web.zoom.us/webinar/regi...
Fred Saad and Marc-Oliver Grimm @grimm_mo will lead an engaging case-based discussion on triplet therapy in metastatic hormone-sensitive #ProstateCancer (mHSPC).
November 4, 2025 at 11:39 AM
A warm invite to join a live, free interactive webinar on November 4, 2025, at CET REGISTER👉
us02web.zoom.us/webinar/regi...
Fred Saad and Marc-Oliver Grimm @grimm_mo will lead an engaging case-based discussion on triplet therapy in metastatic hormone-sensitive #ProstateCancer (mHSPC).
us02web.zoom.us/webinar/regi...
Fred Saad and Marc-Oliver Grimm @grimm_mo will lead an engaging case-based discussion on triplet therapy in metastatic hormone-sensitive #ProstateCancer (mHSPC).
Starting THIS FRIDAY November 7, 2025
DIRECT from NASHVILLE🇺🇸 #UromigosLIVE
WE ARE THERE 🚨Stay Tuned for Coverage!!
Presenting Our Ambassadors
&
OncoAlert 🚨GU Faculty
DIRECT from NASHVILLE🇺🇸 #UromigosLIVE
WE ARE THERE 🚨Stay Tuned for Coverage!!
Presenting Our Ambassadors
&
OncoAlert 🚨GU Faculty
November 4, 2025 at 10:57 AM
Starting THIS FRIDAY November 7, 2025
DIRECT from NASHVILLE🇺🇸 #UromigosLIVE
WE ARE THERE 🚨Stay Tuned for Coverage!!
Presenting Our Ambassadors
&
OncoAlert 🚨GU Faculty
DIRECT from NASHVILLE🇺🇸 #UromigosLIVE
WE ARE THERE 🚨Stay Tuned for Coverage!!
Presenting Our Ambassadors
&
OncoAlert 🚨GU Faculty
Join Vérane Achard and Bertrand Timbal for this Manuscript2Practice series on postoperative #ProstateCancer recurrence 👉 mirrorsmed.org/m2p-postoper...
brought to you by our collaborators at Mirrors of Medicine.
brought to you by our collaborators at Mirrors of Medicine.
November 1, 2025 at 10:37 AM
Join Vérane Achard and Bertrand Timbal for this Manuscript2Practice series on postoperative #ProstateCancer recurrence 👉 mirrorsmed.org/m2p-postoper...
brought to you by our collaborators at Mirrors of Medicine.
brought to you by our collaborators at Mirrors of Medicine.
THE #ESMO25 COMPLETE Newsletter by OncoAlert 🚨MONDAY Nov 3rd is the FINAL DAY TO GET IT‼️ TO GET IT REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
5⃣0⃣of our pick of TOP Trials Presented in Berlin🇩🇪
5⃣0⃣of our pick of TOP Trials Presented in Berlin🇩🇪
October 31, 2025 at 2:43 PM
THE #ESMO25 COMPLETE Newsletter by OncoAlert 🚨MONDAY Nov 3rd is the FINAL DAY TO GET IT‼️ TO GET IT REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
5⃣0⃣of our pick of TOP Trials Presented in Berlin🇩🇪
5⃣0⃣of our pick of TOP Trials Presented in Berlin🇩🇪
The OncoAlert 🚨 TOP STACK: IMvigor011
In muscle-invasive #BladderCancer after cystectomy, ctDNA-guided adjuvant therapy with atezolizumab significantly improved disease-free and overall survival compared with placebo, while ctDNA-negative patients maintained excellent outcomes w/o additional Tx
In muscle-invasive #BladderCancer after cystectomy, ctDNA-guided adjuvant therapy with atezolizumab significantly improved disease-free and overall survival compared with placebo, while ctDNA-negative patients maintained excellent outcomes w/o additional Tx
October 31, 2025 at 10:00 AM
The OncoAlert 🚨 TOP STACK: IMvigor011
In muscle-invasive #BladderCancer after cystectomy, ctDNA-guided adjuvant therapy with atezolizumab significantly improved disease-free and overall survival compared with placebo, while ctDNA-negative patients maintained excellent outcomes w/o additional Tx
In muscle-invasive #BladderCancer after cystectomy, ctDNA-guided adjuvant therapy with atezolizumab significantly improved disease-free and overall survival compared with placebo, while ctDNA-negative patients maintained excellent outcomes w/o additional Tx
Our Collaborators at @mirrorsofmedicine.bsky.social would like to Invite you to Join The Global Forum on GU Oncology info here👉 gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
October 30, 2025 at 2:41 PM
Our Collaborators at @mirrorsofmedicine.bsky.social would like to Invite you to Join The Global Forum on GU Oncology info here👉 gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
The OncoAlert TOP STACK: DESTINY Breast 09
T-DXd plus pertuzumab significantly improves outcomes versus THP across all subgroups of HER2-positive advanced or metastatic #BreastCancer , with a consistent safety profile.
T-DXd plus pertuzumab significantly improves outcomes versus THP across all subgroups of HER2-positive advanced or metastatic #BreastCancer , with a consistent safety profile.
October 30, 2025 at 10:00 AM
The OncoAlert TOP STACK: DESTINY Breast 09
T-DXd plus pertuzumab significantly improves outcomes versus THP across all subgroups of HER2-positive advanced or metastatic #BreastCancer , with a consistent safety profile.
T-DXd plus pertuzumab significantly improves outcomes versus THP across all subgroups of HER2-positive advanced or metastatic #BreastCancer , with a consistent safety profile.
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic #BreastCancer
www.nejm.org/doi/10.1056/...
combination of trastuzumab deruxtecan and pertuzumab yielded a substantial progression-free survival benefit without new safety concerns
www.nejm.org/doi/10.1056/...
combination of trastuzumab deruxtecan and pertuzumab yielded a substantial progression-free survival benefit without new safety concerns
October 30, 2025 at 9:33 AM
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic #BreastCancer
www.nejm.org/doi/10.1056/...
combination of trastuzumab deruxtecan and pertuzumab yielded a substantial progression-free survival benefit without new safety concerns
www.nejm.org/doi/10.1056/...
combination of trastuzumab deruxtecan and pertuzumab yielded a substantial progression-free survival benefit without new safety concerns
You are warmly invited to join a live, free interactive webinar on November 4, 2025, at 18:00 CET REGISTER👉 us02web.zoom.us/webinar/regi...
Fred Saad and Marc-Oliver Grimm will lead an engaging case-based discussion on triplet therapy in metastatic hormone-sensitive prostate cancer (mHSPC).
Fred Saad and Marc-Oliver Grimm will lead an engaging case-based discussion on triplet therapy in metastatic hormone-sensitive prostate cancer (mHSPC).
October 29, 2025 at 2:46 PM
You are warmly invited to join a live, free interactive webinar on November 4, 2025, at 18:00 CET REGISTER👉 us02web.zoom.us/webinar/regi...
Fred Saad and Marc-Oliver Grimm will lead an engaging case-based discussion on triplet therapy in metastatic hormone-sensitive prostate cancer (mHSPC).
Fred Saad and Marc-Oliver Grimm will lead an engaging case-based discussion on triplet therapy in metastatic hormone-sensitive prostate cancer (mHSPC).
LEAP 012 Update/ Source MERCK
Merck and Eisai announced results from the Phase 3 LEAP-012 trial evaluating the combination of pembrolizumab and lenvatinib TACE in unresectable, non-metastatic hepatocellular carcinoma.
did not achieve statistical significance for OS
www.merck.com/news/merck-a...
Merck and Eisai announced results from the Phase 3 LEAP-012 trial evaluating the combination of pembrolizumab and lenvatinib TACE in unresectable, non-metastatic hepatocellular carcinoma.
did not achieve statistical significance for OS
www.merck.com/news/merck-a...
October 29, 2025 at 12:07 PM
LEAP 012 Update/ Source MERCK
Merck and Eisai announced results from the Phase 3 LEAP-012 trial evaluating the combination of pembrolizumab and lenvatinib TACE in unresectable, non-metastatic hepatocellular carcinoma.
did not achieve statistical significance for OS
www.merck.com/news/merck-a...
Merck and Eisai announced results from the Phase 3 LEAP-012 trial evaluating the combination of pembrolizumab and lenvatinib TACE in unresectable, non-metastatic hepatocellular carcinoma.
did not achieve statistical significance for OS
www.merck.com/news/merck-a...
UPDATE: LITESPARK-011
NEWS FROM INDUSTRY/ Source MERCK
Merck & Eisai announce LITESPARK-011 trial met its 1ry endpoint, showing belzutifan + lenvatinib significantly improved PFS 📈 Vs with cabozantinib in adv RCC who progressed after anti–PD-1/L1 therapy. #KidneyCancer
www.merck.com/news/merck-a...
NEWS FROM INDUSTRY/ Source MERCK
Merck & Eisai announce LITESPARK-011 trial met its 1ry endpoint, showing belzutifan + lenvatinib significantly improved PFS 📈 Vs with cabozantinib in adv RCC who progressed after anti–PD-1/L1 therapy. #KidneyCancer
www.merck.com/news/merck-a...
October 28, 2025 at 11:25 AM
UPDATE: LITESPARK-011
NEWS FROM INDUSTRY/ Source MERCK
Merck & Eisai announce LITESPARK-011 trial met its 1ry endpoint, showing belzutifan + lenvatinib significantly improved PFS 📈 Vs with cabozantinib in adv RCC who progressed after anti–PD-1/L1 therapy. #KidneyCancer
www.merck.com/news/merck-a...
NEWS FROM INDUSTRY/ Source MERCK
Merck & Eisai announce LITESPARK-011 trial met its 1ry endpoint, showing belzutifan + lenvatinib significantly improved PFS 📈 Vs with cabozantinib in adv RCC who progressed after anti–PD-1/L1 therapy. #KidneyCancer
www.merck.com/news/merck-a...
LITESPARK-022 Update
NEWS FROM INDUSTRY Source: MERCK
Merck announced positive topline results from LITESPARK-022 trial, showing that pembrolizumab combined with belzutifan significantly improved DFS 📈 Vs pembrolizumab alone in patients with RCC #KidneyCancer
www.merck.com/news/merck-a...
NEWS FROM INDUSTRY Source: MERCK
Merck announced positive topline results from LITESPARK-022 trial, showing that pembrolizumab combined with belzutifan significantly improved DFS 📈 Vs pembrolizumab alone in patients with RCC #KidneyCancer
www.merck.com/news/merck-a...
October 28, 2025 at 11:19 AM
LITESPARK-022 Update
NEWS FROM INDUSTRY Source: MERCK
Merck announced positive topline results from LITESPARK-022 trial, showing that pembrolizumab combined with belzutifan significantly improved DFS 📈 Vs pembrolizumab alone in patients with RCC #KidneyCancer
www.merck.com/news/merck-a...
NEWS FROM INDUSTRY Source: MERCK
Merck announced positive topline results from LITESPARK-022 trial, showing that pembrolizumab combined with belzutifan significantly improved DFS 📈 Vs pembrolizumab alone in patients with RCC #KidneyCancer
www.merck.com/news/merck-a...
Our Collaborators at @high5md have gathered top international experts in Lung Cancer
WATCH HERE: buff.ly/3NuVFAr
They have uploaded their full reports from ESMO25 and available on demand. Visit them for the Top News out of Berlin!
WATCH HERE: buff.ly/3NuVFAr
They have uploaded their full reports from ESMO25 and available on demand. Visit them for the Top News out of Berlin!
October 24, 2025 at 1:43 PM
Our Collaborators at @high5md have gathered top international experts in Lung Cancer
WATCH HERE: buff.ly/3NuVFAr
They have uploaded their full reports from ESMO25 and available on demand. Visit them for the Top News out of Berlin!
WATCH HERE: buff.ly/3NuVFAr
They have uploaded their full reports from ESMO25 and available on demand. Visit them for the Top News out of Berlin!
Experts joined COR2ED in Berlin at ESMO 2025 to share their insights on the latest data on GU, lung, breast, gynecological & upper GI cancers. Watch Here cor2ed.com/esmo-2025/hi...
October 24, 2025 at 12:00 PM
Experts joined COR2ED in Berlin at ESMO 2025 to share their insights on the latest data on GU, lung, breast, gynecological & upper GI cancers. Watch Here cor2ed.com/esmo-2025/hi...
Join the Advances in Lung Cancer 2025 Highlights webinar on Dec 1, 2025, at 7:30 PM (CET) for an expert-led virtual session hosted by VJOncology
REGISTER HERE:
us06web.zoom.us/webinar/regi...
REGISTER HERE:
us06web.zoom.us/webinar/regi...
October 24, 2025 at 11:00 AM
Join the Advances in Lung Cancer 2025 Highlights webinar on Dec 1, 2025, at 7:30 PM (CET) for an expert-led virtual session hosted by VJOncology
REGISTER HERE:
us06web.zoom.us/webinar/regi...
REGISTER HERE:
us06web.zoom.us/webinar/regi...
We invite you to follow VJOncology’s exclusive coverage of ESMO 2025 in Berlin
WATCH HERE 👉 bit.ly/4qa5j06
Great in-depth reporting on pivotal trials, emerging therapies, and expert insights shaping the future of oncology.
WATCH HERE 👉 bit.ly/4qa5j06
Great in-depth reporting on pivotal trials, emerging therapies, and expert insights shaping the future of oncology.
October 23, 2025 at 1:43 PM
We invite you to follow VJOncology’s exclusive coverage of ESMO 2025 in Berlin
WATCH HERE 👉 bit.ly/4qa5j06
Great in-depth reporting on pivotal trials, emerging therapies, and expert insights shaping the future of oncology.
WATCH HERE 👉 bit.ly/4qa5j06
Great in-depth reporting on pivotal trials, emerging therapies, and expert insights shaping the future of oncology.
Our collaborators at high5Oncology have brought together leading international experts in #BreastCancer . WATCH HERE👉 buff.ly/3NuVFAr
Missed it live? All the great expert insights from Berlin are now ON DEMAND! Follow for the latest updates and analysis from the meeting
Missed it live? All the great expert insights from Berlin are now ON DEMAND! Follow for the latest updates and analysis from the meeting
October 23, 2025 at 11:00 AM
Our collaborators at high5Oncology have brought together leading international experts in #BreastCancer . WATCH HERE👉 buff.ly/3NuVFAr
Missed it live? All the great expert insights from Berlin are now ON DEMAND! Follow for the latest updates and analysis from the meeting
Missed it live? All the great expert insights from Berlin are now ON DEMAND! Follow for the latest updates and analysis from the meeting
Dear Colleagues, Our Collaborators at COR2ED Invite you to watch Highlights from #ESMO25
WATCH HERE 👉 cor2ed.com/esmo-2025/br...
Straight from Berlin, Experts share their views on new data on #BreastCancer & #GynOnc
NOW ON DEMAND
WATCH HERE 👉 cor2ed.com/esmo-2025/br...
Straight from Berlin, Experts share their views on new data on #BreastCancer & #GynOnc
NOW ON DEMAND
October 23, 2025 at 10:02 AM
Dear Colleagues, Our Collaborators at COR2ED Invite you to watch Highlights from #ESMO25
WATCH HERE 👉 cor2ed.com/esmo-2025/br...
Straight from Berlin, Experts share their views on new data on #BreastCancer & #GynOnc
NOW ON DEMAND
WATCH HERE 👉 cor2ed.com/esmo-2025/br...
Straight from Berlin, Experts share their views on new data on #BreastCancer & #GynOnc
NOW ON DEMAND
Colleagues, the Complete #ESMO25 OncoAlert Newsletter is coming Oct 27‼️ GET IT HERE👉 oncoalert.m-pages.com/nhMpwe/oncoa...
50 of our PICKS of TOP Trials out of Berlin 🇩🇪
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social
50 of our PICKS of TOP Trials out of Berlin 🇩🇪
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social
October 22, 2025 at 2:25 PM
Colleagues, the Complete #ESMO25 OncoAlert Newsletter is coming Oct 27‼️ GET IT HERE👉 oncoalert.m-pages.com/nhMpwe/oncoa...
50 of our PICKS of TOP Trials out of Berlin 🇩🇪
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social
50 of our PICKS of TOP Trials out of Berlin 🇩🇪
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social
Our collaborators at high5Oncology have brought together leading international experts in GU cancer, and their insights are now available online—follow for the latest news and expert analysis from Berlin!
high5oncology.tv/meeting-cove...
high5oncology.tv/meeting-cove...
October 21, 2025 at 9:00 AM
Our collaborators at high5Oncology have brought together leading international experts in GU cancer, and their insights are now available online—follow for the latest news and expert analysis from Berlin!
high5oncology.tv/meeting-cove...
high5oncology.tv/meeting-cove...
Prof. Viktor Grünwald shares his renal cell carcinoma highlights from ESMO 2025 as he reviews the latest data from the LenCabo, KEYMAKER-U03 and CLEAR studies. He also discusses staging of disease with the radiolabelled peptide ([68Ga]Ga-DPI-4452).
cor2ed.com/esmo-2025/re...
cor2ed.com/esmo-2025/re...
October 21, 2025 at 8:30 AM
Prof. Viktor Grünwald shares his renal cell carcinoma highlights from ESMO 2025 as he reviews the latest data from the LenCabo, KEYMAKER-U03 and CLEAR studies. He also discusses staging of disease with the radiolabelled peptide ([68Ga]Ga-DPI-4452).
cor2ed.com/esmo-2025/re...
cor2ed.com/esmo-2025/re...
Join the Advances in Lung Cancer 2025 Highlights webinar on Dec 1, 2025, at 7:30 PM (CET) for an expert-led virtual session hosted by VJOncology, featuring the latest clinical breakthroughs, trial updates, and insights from major 2025 lung cancer meetings
us06web.zoom.us/webinar/regi...
us06web.zoom.us/webinar/regi...
October 20, 2025 at 12:58 PM
Join the Advances in Lung Cancer 2025 Highlights webinar on Dec 1, 2025, at 7:30 PM (CET) for an expert-led virtual session hosted by VJOncology, featuring the latest clinical breakthroughs, trial updates, and insights from major 2025 lung cancer meetings
us06web.zoom.us/webinar/regi...
us06web.zoom.us/webinar/regi...